SuperworthVyome HIND
- Market cap
- $12.6M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.2M−23% | $2M−36% | $1.9M−15% | $2M−13% | $84.5K−96% | $1.8M−9% | $198.6K−90% | $50K−98% | $34.6K−59% | n/a | $31.6K−84% | $27K−46% | |
| Cost of revenue | $867K+24% | $140K−91% | $779K−27% | $831K−22% | $47.4K−95% | $486K+247% | $44.2K−94% | $25.7K−97% | $16.6K−65% | n/a | $14.9K−66% | $15.3K−41% |
| Gross profit | $1.3M−39% | $1.8M+15% | $1.2M−5% | $1.1M−5% | $37.1K−97% | $1.3M−28% | $154.4K−87% | $24.2K−98% | $18.1K−51% | n/a | $16.6K−89% | $11.7K−52% |
| R&D | $542K−7% | $739K+60% | $484K+7% | $399K−31% | $66.8K−88% | $521K−30% | $90.3K−81% | $80.1K−80% | $39.7K−41% | n/a | $666.4K+638% | $506.7K+533% |
| SG&A | $1.8M−31% | $1.4M−35% | $2.9M+33% | $2.6M+18% | $246.8K−86% | $7.5M+438% | $259.6K−91% | $265.4K−90% | $844.3K+242% | n/a | $477.6K+84% | $364.9K+38% |
| −$3.9M−69% | −$1.9M−89% | −$2.2M−61% | −$2.1M−48% | −$281K−93% | −$1.7M−10% | −$199K−91% | −$324.2K−84% | −$8.6M+2952% | n/a | −$1.1M+468% | −$862.6K+166% | |
| Interest expense | n/a | n/a | −$9K | n/a | $45.7K | n/a | $55K | $56.1K | $25.6K−44% | n/a | $2.8K−95% | $3.3K−94% |
| Pre-tax income | −$3.5M−72% | −$1.7M−90% | −$2.2M−18% | −$1.6M−55% | −$1.6M−55% | −$1.8M+5% | $1.5M | −$2.6M+66% | n/a | n/a | n/a | n/a |
| $3K | $31K | $14K+0% | $15K+275% | $6K+100% | $5K−84% | $7K−50% | $8K−47% | n/a | n/a | n/a | n/a | |
| Net income | −$3.5M−71% | −$1.7M−90% | −$2.2M−18% | −$1.6M−54% | −$547.8K−85% | −$1.8M+4% | −$294K−87% | −$308.8K−81% | −$8.4M+1440% | −$1.2M−30% | −$962.9K+228% | −$685.6K+122% |
| −$5936.00−96% | −$644.00−100% | −$541.48−94% | −$366.24−94% | −$1419.10−76% | −$247.00−62% | −$761.59+41% | −$799.90+118% | −$3.12−100% | n/a | −$0.15−100% | −$0.10−100% | |
| 595+665% | 2.6K+3037% | 4K+1275% | 4.4K+677% | 386−35% | 7.1K+170% | 386−91% | 386−91% | 2.8M+714535% | n/a | 6.7M+1733131% | 7M+1818172% |
Net income: 17 periods, Q2 FY20 to Q2 FY24: not printed by the filing, worked out from its own lines.
EPS, diluted: 7 periods, Q4 FY15 to Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: 9 periods, Q4 FY15 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q2 FY25 and Q2 FY26: not printed by the filing, worked out from its own lines.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Vyome's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| HINDVyome | $12.6M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Vyome
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .